<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00580450</url>
  </required_header>
  <id_info>
    <org_study_id>(ST 1472)</org_study_id>
    <secondary_id>ST 1472 06/01/27</secondary_id>
    <nct_id>NCT00580450</nct_id>
  </id_info>
  <brief_title>Thymosin Alfa 1 in Recipients of Allogeneic Hematopoietic Transplantation for Hematological Malignancies</brief_title>
  <official_title>Phase I/II Clinical Trial on Thymosin Alfa 1 of Allogeneic Hematopoietic Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Of Perugia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Of Perugia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine safety and efficacy of 16 weeks treatment with&#xD;
      thymosin alpha 1 given at 1.6 mg dose once daily by subcutaneous injection in adult patients&#xD;
      with hematological undergone allogenic bone marrow transplantation and CMV positive.&#xD;
&#xD;
      The efficacy will be explored assessing the ability of thymosin alpha1 to prevent the&#xD;
      infection complications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, monocenter, explorative study . A total of 9 patients will be included&#xD;
      in the study in three sequential cohort of 3 patients each. Patients will enter into the&#xD;
      study after meeting the inclusion and exclusion criteria and signing the Informed Consent&#xD;
      Form.&#xD;
&#xD;
      The first three patients will be treated for 16 weeks starting 40 days after transplantation;&#xD;
      if all three patients will complete the treatment period without any serious treatment&#xD;
      related adverse event then the recruitment of second cohort of patients will be opened and&#xD;
      patients treated starting from 20 days after transplantation. The same procedure will be&#xD;
      applied for the third cohort of patients starting treatment from day of transplantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2007</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy in terms of improvement of immunological reconstitution, infectious mortality; safety as prevention of GvHD.</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Hematological Malignancies</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymosin alpha 1</intervention_name>
    <description>1.6 mg sc once a day for 16 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed written informed consent.&#xD;
&#xD;
          2. Age &gt; 18 or &lt; 55.&#xD;
&#xD;
          3. Patients with AML, ALL, or other haematological malignancies with an indication to&#xD;
             transplant with or without a matched donor undergoing allogenic haploidentical&#xD;
             hematopoietic transplantation (see Appendix 2) in any of the following categories:&#xD;
&#xD;
               -  Patients in first complete remission (CR) at high risk of relapse because of&#xD;
                  unfavourable cytogenetics, such as:&#xD;
&#xD;
                    -  t (9;22)&#xD;
&#xD;
                    -  11q23 translocation&#xD;
&#xD;
                    -  complex karyotype&#xD;
&#xD;
                    -  t (8;12)/ETV6-AML&#xD;
&#xD;
                    -  t (6;9)/DEK-CAN&#xD;
&#xD;
                    -  t (11;14)(q15,q11)&#xD;
&#xD;
                    -  Trisomy 13&#xD;
&#xD;
                    -  FLT-3/ITD&#xD;
&#xD;
               -  Or other adverse prognostic factors, such as:&#xD;
&#xD;
                    -  Secondary leukemia&#xD;
&#xD;
                    -  CR after second line treatment&#xD;
&#xD;
                    -  High blast count&#xD;
&#xD;
                    -  Biphenotypic leukemia&#xD;
&#xD;
               -  Patients in 2nd or 3rd CR or in chemoresistant relapse&#xD;
&#xD;
          4. Recipient CMV positive as measured by pp65 antigenemia and PCR&#xD;
&#xD;
          5. Adequate cardiac function: Asymptomatic of if symptomatic then left ventricular&#xD;
             ejection fraction at rest be &gt;45% and must improve with exercise,&#xD;
&#xD;
          6. Adequate hepatic function: &lt;2 x GOT and GPT and &lt;2.0 mg total serum bilirubin unless&#xD;
             liver is involved in disease,&#xD;
&#xD;
          7. Adequate renal function: Serum creatinine within normal range or if serum creatinine&#xD;
             outside normal range then creatinine clearance &gt;50 ml/min,&#xD;
&#xD;
          8. Adequate Pulmonary function: Diffusion capacity &gt;50% of predicted (corrected for&#xD;
             hemoglobin)&#xD;
&#xD;
          9. Normal TSH or evidence of proper thyroid hormone replacement.&#xD;
&#xD;
         10. For women of childbearing potential participating in the study, abstinence from sexual&#xD;
             intercourses or use of a reliable form of effective contraception during the treatment&#xD;
             period. These may include, but are not limited to, birth control pills, IUDs, condoms,&#xD;
             diaphragms, implants, surgical sterilization, or being in a post-menopausal state.&#xD;
&#xD;
         11. Negative pregnancy test prior to first study medication dose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of active hepatitis (B and/or C) or cirrhosis&#xD;
&#xD;
          2. HIV positive&#xD;
&#xD;
          3. Presence of any other active, uncontrolled bacterial, viral or fungal infection&#xD;
&#xD;
          4. Neurological or psychiatric dysfunctions which would impair compliance with the&#xD;
             medical regimens and/or transplantation toleration&#xD;
&#xD;
          5. Concomitant or prior history of malignancy other than surgically cured in situ&#xD;
             carcinoma of the cervix.&#xD;
&#xD;
          6. Pregnancy as documented by a urine pregnancy test or lactation.&#xD;
&#xD;
          7. Any indication that the patient would not comply with the conditions of the study&#xD;
             protocol.&#xD;
&#xD;
          8. Previous treatment with thymosin alpha 1.&#xD;
&#xD;
          9. Simultaneous participation in another investigational drug study or participation in&#xD;
             any clinical trial involving investigational drugs within 3 months before study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Velardi, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hematology Section, University of Perugia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrae Velardi, MD, Prof.</last_name>
    <phone>+39 075 578 3151</phone>
    <email>velardi@unipg.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hematology Section, University of Perugia</name>
      <address>
        <city>Perugia</city>
        <zip>06122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Massimo F Martelli, Prof</last_name>
      <phone>+39 075 578 4170</phone>
      <email>ematol@unipg.it</email>
    </contact>
    <contact_backup>
      <last_name>Franco Aversa, Prof</last_name>
      <phone>+39 075 578 4179</phone>
      <email>aversa@unipg.it</email>
    </contact_backup>
    <investigator>
      <last_name>Katia Perruccio, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luigina Romani, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>December 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2007</study_first_posted>
  <last_update_submitted>December 21, 2007</last_update_submitted>
  <last_update_submitted_qc>December 21, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2007</last_update_posted>
  <responsible_party>
    <name_title>Andrea Velardi</name_title>
    <organization>Hematology Section, University of Perugia</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thymalfasin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

